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Abstract 
Background: In the Kingdom of Saudi Arabia (KSA), Leishmania major and L. tropica are the main causative agents 
of Old World cutaneous leishmaniasis (CL). The national CL treatment regimen consists of topical 1% clotrimazole/2% 
fusidic acid cream followed by 1–2 courses of intralesional sodium stibogluconate (SSG); however, treatment efficacy 
is highly variable and the reasons for this are not well understood. In this study, we present a complete epidemiologi‑
cal map of CL and determined the efficacy of the standard CL treatment regime in several endemic regions of KSA.
Results: Overall, three quarters of patients in all CL‑endemic areas studied responded satisfactorily to the current 
treatment regime, with the remaining requiring only an extra course of SSG. The majority of unresponsive cases were 
infected with L. tropica. Furthermore, the development of secondary infections (SI) around or within the CL lesion 
significantly favoured the treatment response of L. major patients but had no effect on L. tropica cases.
Conclusions: The response of CL patients to a national treatment protocol appears to depend on several factors, 
including Leishmania parasite species, geographical location and occurrences of SI. Our findings suggest there is a 
need to implement alternative CL treatment protocols based on these parameters.
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Background
Old World cutaneous leishmaniasis (CL) is endemic 
throughout the East Mediterranean Region (EMR) [1]. 
According to the World Health Organization, in recent 
years, over 150,000 human CL cases were reported in 
16 EMR countries [2]. Various factors contribute to 
the spread of CL in this region, including uncontrolled 
urbanization, irrigation, governmental sector integration, 
socio-economic factors and lack of health education [3]. 
War is another important factor responsible for CL out-
breaks in the region, with over 200,000 people infected 
during the military conflict in Afghanistan [4] and a simi-
lar number affected since the start of the Syrian civil war 
[5–9].
CL is the second most important vector-borne disease 
in the Kingdom of Saudi Arabia (KSA) after dengue fever. 
Most of the reported CL cases are concentrated in the 
regions of Al Ahsa, Al Qassem, Riyadh, Asir, Hail and Al 
Madinah [10–22]. Since the early 1980’, KSA has imple-
mented a national CL control programme consisting not 
only in carrying out case detection in focus areas, but 
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also involving vector and reservoir control. Due to this 
well-designed national control programme, the number 
of formally registered CL cases in KSA has dropped since 
1987, from ~17,000 to ~2000 cases per year in 2015 [14]. 
However, these official surveillance figures are likely to 
underestimate the prevalence and disease burden due to 
the number of unreported cases [14]. In addition to other 
non-communicable diseases, CL control in KSA is par-
ticularly important because of the millions of visitors that 
this country receives annually due to religious activities. 
Furthermore, around 35% of the country’s work force 
consists of visitors arriving from other leishmaniasis-
endemic countries. Both anthroponotic (caused by L. 
tropica) [10, 17, 22] and zoonotic (caused by L. major) [6, 
15, 23, 24] CL have been reported in KSA, but very lit-
tle is currently known about the national distribution of 
these parasite species.
Current drug treatment protocols for patients with Old 
World CL vary between EMR countries. Intralesional 
pentostam or sodium stibogluconate (SSG) is commonly 
used in this region, despite their high toxicity and the 
increasing number of unresponsive individuals. Cur-
rently, SSG is the second-line treatment choice for CL 
in KSA. In most cases, it is administered if the patient 
remains unresponsive (i.e. lack of re-epithelisation) after 
treatment with topical broad-spectrum antimicrobials 
(azoles and/or antibiotics; first line treatment). Topi-
cal paromomycin, either alone or in combination with 
gentamicin, was found to be effective in treatment of 
L. major cases in Tunisia [25], although it has not been 
implemented in KSA.
In this study, we present a complete epidemiological 
map of CL in KSA, including the clinical features associ-
ated with the two main parasite species, L. major and L. 
tropica. Furthermore, we show evidence that the efficacy 
of the current CL treatment protocol is highly dependent 
on the parasite species associated with the infection, geo-
graphical location and possibly also to the development 
of secondary infections in or around the lesion.
Methods
Sample collection and clinical data
Skin aspirate samples from a total of 104 adult CL-
patients were collected from several cities or towns 
in KSA. Overall, this represented around 7% of all 
reported cases of CL in KSA in 2012. Case record stud-
ies and information sheets were obtained for all patients. 
This information was anonymised and re-labelled with 
the appropriate study code. The recorded informa-
tion included all relevant clinical data (i.e. lesion size, 
number(s) and location(s) on the body, clinical features 
and treatment response, patient age and sex) and is pro-
vided in Additional file 1: Table S1.
Parasite isolation and in vitro culture
Parasite samples were collected by wound aspiration 
from Leishmania-infected patients after one month 
of lesion appearance using 200–300  µl of sterile PBS. 
Wound aspirates were transferred to plastic flasks (in 
triplicate) containing Leishmania culture medium 
M199 (Gibco, Grand Island, NY, USA) supplemented 
with 15% heat-inactivated foetal bovine serum (Invitro-
gen), 1.5% BME vitamins (Sigma-Aldrich, Saint Louis, 
MO, USA) and 25 µg/ml gentamycin sulphate (Sigma-
Aldrich, Saint Louis, MO, USA). Leishmania cultures 
were maintained for several days at 27  °C and parasite 
DNA was extracted from logarithmic phase cultures 
using the DNeasy Blood and Tissue kit (Qiagen, Ger-
mantown, MD, USA) following the manufacturer’s 
instructions.
Drug treatment
Clinically diagnosed patients were referred for treat-
ment as recommended by the current KSA leishmania-
sis treatment policy. This begins with the application of 
topical clotrimazole (1%) and/or fusidic acid (2%) for the 
treatment of secondary infections (i.e. bacterial, fungal 
or both). If after one week of treatment healing (re-epi-
thelisation) was not initiated, the patient then received 
one course (of 14 injections each) of intralesional SSG 
(20 mg/kg/day) (Additional file 2: Figure S1). All patients 
receiving SSG treatment were evaluated before and after 
treatment for complete blood counts and levels of aspar-
tate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, amylase and gamma glutamyltransferase. A 
few patients (n = 16) from the unsatisfactory responsive 
group (i.e. those with lesion extension, formation of satel-
lite lesions or recurrence) were referred for a 3rd course 
of intramuscular SSG (20 mg/kg/day for up to 2 weeks) 
after clinical assessment (blood count, liver and renal 
function analyses).
Identification of secondary infection species and antibiotic 
susceptibility testing
Secondary infections were identified by clinical assess-
ment. Nutrient agar, blood agar, MacConkey agar and 
Sabouraud dextrose agar were used for bacterial and 
fungal culture. Microscopy and biochemical assays were 
carried out to identify microbial species. Antibiotic sus-
ceptibility testing from identified species were performed 
using the semi-automatic analyser Microscan Autoscan-4 
system (Beckman Coulter, Indianapolis, IN, USA). The 
antibiotics tested were ampicillin, azithromycin, cefoxi-
tin, ciprofloxacin, erythromycin, fosfomycin, fusidic acid 
and gentamicin. All the laboratory analyses for microbial 
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identification were carried out at King Abdulaziz Centre 
for Science and Technology (KACST).
Species identification of Leishmania isolates
Identification was performed based on a modified PCR-
restriction fragment length polymorphism (PCR-RFLP) 
method previously described (26). A first PCR reaction 
of 25 µl was set using the Q5 High-Fidelity 2X Master-
mix (New England Biolabs, Ipswich, MA, USA) and the 
primers OL1853 and OL1854 at 200  nM. PCR condi-
tions were as follows: 98 °C for 1 min, 35 cycles of 10 s at 
98 °C, 30 s at 57 °C and 20 s at 72 °C, and a final step at 
72 °C for 1 min. To increase the sensitivity, a second iden-
tical PCR was performed using 1  µl of PCR product as 
template. Then, 20 µl of the PCR product was incubated 
with HaeIII (New England Biolabs) in a 50 µl reaction at 
37 °C for 1 hour and inactivated at 80 °C for 20 min. For 
the analysis, 5 µl of unrestricted PCR product and 20 µl 
of restricted product were run in a 2.5% agarose gel at 
100  V. Leishmania species for each patient sample was 
determined by comparing its restriction pattern with L. 
major and L. tropica reference reactions. Unrestricted 
PCR products were also sequenced (Sanger sequencing; 
Source Biosciences, UK) to confirm product specificity.
Data analysis
All factors affecting the treatment responses were 
included in our analyses (i.e. clinical features, number 
and sites of the lesions, geographical area and parasite 
species). Fisher’s exact test and Chi-square test were used 
to validate the statistical significance among the differ-
ent factors. IMB SPSS Statistics 21 (IBM Corp. Released 
2012. IBM SPSS Statistics for Windows, Version 21.0. 
Armonk, NY: IBM Corp.) was employed for all data 
analysis. Software ArcGIS 10 (ESRI 2011, ArcGIS Desk-
top: Release 10. Redlands, CA: Environmental Systems 
Research Institute) was used to map the distribution of 
parasite species and patient response to anti-leishmanial 
drug treatment across the regions, and in relation to ele-
vation based on gridded Global Relief Data (ETOPO2) 
data, based on the geographical coordinates (latitude and 
longitude) of each site.
Results
Identification of Leishmania species
In KSA, Old World CL is mainly diagnosed by clini-
cal assessment and microscopic examination, but not 
molecularly [10]. The infective Leishmania species is 
inferred based on the appearance, number of lesions and 
potential geographical location where infection may have 
occurred. Using a well-established PCR-RFLP analysis of 
the ITS1 region [10, 26, 27] we identified the Leishma-
nia species present in 104 CL patients (Additional file 2: 
Figures  S2–S5). All 104 CL patients were confirmed to 
be infected with either L. major or L. tropica. Leishma-
nia major was the main species responsible for CL in 
KSA and predominately found in the regions of Al Ahsa 
(East), Al Qassem and Riyadh (Central), and Al Madinah 
(Northwest) (Fig. 1 and Additional file 2: Figures S6-S7). 
Furthermore, L. tropica was the only species found in the 
Southwest regions of Asir and Jazan (Fig.  1 and Addi-
tional file 2: Figure S8). Interestingly, L. tropica was also 
detected in a few cases from the Al Madinah region, with 
one particular village reporting the presence of both L. 
Fig. 1 Distribution of Leishmania species (a) and patient response to anti‑leishmanial treatment (b) within the main CL endemic regions of Saudi 
Arabia. Map was created using software ArcGIS 10 (ESRI 2011, ArcGIS Desktop: Release 10. Redlands, CA: Environmental Systems Research Institute). 
See also detailed maps in Additional file 2: Figures S6, S7 and S8
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major and L. tropica infections (Fig.  1 and Additional 
file 2: Figure S3).
Clinical presentations of CL patients vary depending 
on parasite species
Several clinical features of the CL lesions, along with 
the infecting parasite species, were measured. These 
parameters included size, clinical presentations (i.e. 
papular, nodular or ulcerated nodular), location on the 
body, numbers, and whether satellite lesions were pre-
sent (Table  1). Leishmania major lesions tended to be 
smaller (16.5  mm) than L. tropica ones (22.2  mm). The 
clinical presentations were significantly associated with 
the infecting species (Fisher’s exact test of association; 
P = 0.001745), with relatively similar numbers of each 
lesion type in L. major infections, but a notable skew 
towards ulcerated nodular lesions in L. tropica infections.
The location of lesions was also significantly associ-
ated with the infecting parasite species (P ≤ 0.00001), 
with L. tropica lesions appearing to be more common on 
the arms, face, nose or ear than L. major lesions, which 
are more common on other sites of the body (Table  1). 
Furthermore, the number of lesions was significantly 
associated with the parasite species (P = 7.201×10−5), 
with L. major infections displaying a bi-modal distribu-
tion of 1 lesion or > 6 lesions while L. tropica infections 
all showed ≤ 3 lesions. The presence of satellite lesions 
was also significantly associated with infecting species 
(P = 0.005813), with 57% of L. tropica infections display-
ing satellite lesions compared to 22% in L. major ulcers.
Efficacy of anti‑leishmanial treatment varies depending 
on parasite species and geographical location
Confirmed (medically diagnosed) CL patients were 
referred for anti-leishmanial treatment starting with topi-
cal antifungals alone or in combination with antibiotics 
(first line of treatment) followed by 1–2 courses of IL 
SSG (as described in the Methods section). Overall, 30% 
of L. major-infected patients responded to the first line 
of treatment alone and 82% after SSG courses were com-
pleted (Fig. 2a). However, none of the L. tropica-infected 
patients responded to topical azoles/fusidic acid, and in 
fact 60% did not respond at all to any treatment regimen 
even after receiving 2 courses of SSG (Table 2). Most L. 
tropica unresponsive patients withdrew after receiving 
the second course of SSG. Interestingly, when the treat-
ment responses of patients from different geographical 
locations were compared, 90% of the cases from Central 
(i.e. Riyadh; exclusively L. major-infected) responded 
favourably (within 1 week) to topical azoles/fusidic acid 
alone (Fisherʼs exact test, P = 0.001), whereas two-thirds 
of the cases from the Northwest (Al Madinah; mainly L. 
major-infected) and Southwest (Asir; exclusively L. trop-
ica-infected) responded unsatisfactorily to both lines of 
treatment.
SIs were primarily detected in patients from the East-
ern (35%; exclusively L. major) and Southwest (40%; 
exclusively L. tropica) regions (Fig. 2). Interestingly, 52% 
of L. major patients presenting SIs responded favour-
ably after treatment with just topical azoles/fusidic acid 
(Fisherʼs exact test, P = 0.002; Fig. 2b), with the remain-
ing needing just one course of SSG to heal. Moreover, the 
group of L. major patients lacking SI responded poorly to 
azoles/fusidic acid treatment and many (~38%) remained 
unresponsive after a second SSG course. In contrast, the 
development of SIs did not have an effect upon the treat-
ment response of L. tropica patients (Fig. 2b).
Staphylococcus species isolated from L. major lesions show 
resistance to a variety of antibiotics, including Fusidic Acid
Staphylococcus epidermidis, S. haemolyticus and S. hom-
ins were isolated from 6 L. major patients from Al Ahsa 
region. The resistance profiles (Fig.  3) showed that 6/6 
of S. epidermidis, 4/6 S. homins and 3/6 S. haemolyticus 
isolates are resistant to fusidic acid, which is part of the 
first line of CL treatment in KSA. From these 6 patients, 
4 responded to the first line of treatment (azoles/fusidic 
Table 1 Clinical presentation of CL lesions according to 
infecting parasite species
a Fisher’s exact test of association
b Nodular lesions were found in L. tropica patients from Al Madinah (Al Jadidah) 
and Asir (Etoed)
c Ulcerated nodular lesions were found in two thirds of CL patients. Lesions 
were mainly localized on the face, nose and/or ear
d The criteria used by the Saudi MoH for categorizing the location of the lesions 
is related to the use of traditional outfits, which determines the area of the body 
exposed to sand fly bites
Parasite species L. major L. tropica P‑value
Mean lesion size 16.5 22.2
Lesion feature Papularb 23 0 0.001745
Nodular 27 7
Ulcerated  nodularc 25 14
Lesion  locationd Hand, neck, head 30 2 < 0.00001
Arm 7 12
Trunk, leg, foot 19 0
Face, nose, ear 3 7
Whole body 16 0
Lesion number 1 23 10 < 0.00001
2 9 3
3 5 8
4 4 0
5 7 0
6+ (max. 29) 27 0
Satellite lesions Yes 17 12 0.005813
No 58 9
Page 5 of 9Al‑Salem et al. Parasites Vectors          (2019) 12:195 
acid) and 2 had to receive 1 course of SSG to complete 
healing. Furthermore, all the Staphylococcus species iso-
lated from L. major-infected patients showed resistance 
to azithromycin, whereas S. homins strains were resistant 
to ampicillin, cefoxitin and fosfomycin, and S. haemolyti-
cus strains resistant to ampicillin and erythromycin.
Discussion
Several studies have investigated the clinical profiles of 
CL in Saudi Arabia [15–17, 20, 21, 28]. However, to our 
knowledge, this study is the most comprehensive dataset 
of CL samples collected from patients across the coun-
try. One hundred and four parasite isolates were col-
lected from infected CL patients from the main endemic 
regions of KSA and the species molecularly identified 
by PCR-RFLP. Each patient was medically assessed and 
referred for treatment according to the KSA national 
treatment policy.
Leishmania major was found in patients from Al Ahsa, 
Riyadh, Al-Qassim and Al-Madinah, all from arid or 
semi-arid areas at a low altitude (not sea level), while L. 
tropica was exclusively detected in patients from Asir, 
Fig. 2 Correlation between responses to drug treatment and CL endemic regions (a), and development of secondary infections (SI) and treatment 
response (b). a Distribution by region of 104 patients with L. major or L. tropica infections confirmed by culture, PCR‑RFLP or clinical features. Patients 
from the Central region (exclusively infected with L. major) had a significantly higher response (healing; P = 0.001, Fisher’s exact test) to the first 
line of treatment compared to other CL‑endemic regions studied. In addition, patients from the Eastern region, responded significantly favorably 
(P = 0.001; Fisher’s exact test) to the first course of SSG compared to those from both Northwest and Southwest regions. b Data for 96 patients with 
L. major (n = 75) or L. tropica (n = 21) infections confirmed by culture or PCR‑RFLP. A significant P = 0.0002 (Chi‑square test) response to first line of 
treatment was observed only in L. major patients that had developed SI. However, there were no significant differences in L. tropica patients with or 
without SI. Abbreviations: SI, presence of secondary infections; No SI, absence of secondary infections
Table 2 Correlation between location of CL lesions and patient response to drug treatment. Data for 96 patients with L. major or L. 
tropica infections confirmed by culture or PCR‑RFLP
a 85% of patients that did not respond to drug treatment were infected with L. tropica
b Fisher’s exact test
c Ulcerated L. tropica cases with secondary infection
d All cases were L. major patients with apparent secondary infections
e Cases with satellite lesions
f Cases with multiple lesions receiving more than two courses of stibogluconate (SSG)
Lesion location % Patients responding to drug treatment (healing)
1st line (Azoles/
fusidic acid)
2nd line (SSG) 1st 
course
2nd line (SSG) 2nd 
course
Unresponsive  casesa P‑valueb
Head, neck or hand 41 (n = 13) 37 (n = 12) 5 (n = 2) 16 (n = 15) 0.0192 (n = 32)
Arms 32 (n = 6) 0 (n = 0) 21 (n = 4) 47 (n = 9) 0.2 (n = 19)
Trunk, legs or feet 32 (n = 6) 63 (n = 12) 0 (n = 0) 5c (n = 1) 0.02 (n = 19)
Face, nose or ear 10 (n = 1) 20d (n = 2) 20 (n = 2) 50e (n = 5) 0.5 (n = 10)
Disseminated (whole body) 13 (n = 2) 31 (n = 5) 13 (n = 2) 43f (n = 7) 0.7 (n = 16)
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Jazan and Al-Jadidah (Al-Madinah) (high altitude) [29]. 
Interestingly, both L. major and L. tropica parasites were 
isolated in the Al-Jadidah village and from regions at sim-
ilar altitude (~600 m above sea level). We speculate that 
this is likely due to L. tropica-infected patients migrating 
to this region, as the climatic conditions and ecology of 
Al-Jadidah do not favour transmission of L. tropica by 
its main vector, Phlebotomus sergenti [29]. Furthermore, 
we have recently characterized the sand fly vectors from 
the same Al-Madinah locations and found no evidence of 
Ph. sergenti in this region, although it has been previously 
reported in other areas [11, 15, 22, 29].
The clinical features of L. major patients appear to vary 
according to the endemic area [28]. Although we did not 
find statistically significant differences between the dif-
ferent regions sampled in this study, we observed that 
ulcerated nodular lesions were found predominantly in 
cases from Al Ahsa, whereas nodular and papular lesions 
were common in Al Madinah and Riyadh. Furthermore, 
multiple lesions were found in over half of L. major 
patients from Al Ahsa. This differs from previous reports 
where only 5% of the patients (presumably also infected 
with L. major) presented multiple lesions [28, 30]. These 
differences may be due in part to higher exposure of peo-
ple to sand fly bites as most of the CL patients from Al 
Ahsa that took part in this study were migrant construc-
tion workers.
Several factors may account for differences in treat-
ment response, including the possible presence of differ-
ent drug-resistant parasites, the nutritional and immune 
status of the patients and their genetic backgrounds. 
In addition, sand fly saliva could also play an impor-
tant role in disease outcome as saliva from Ph. papatasi 
(L. major vector) has been reported to trigger either 
a Type-I (regarded as protective against a Leishmania 
infection) or II delayed-type hypersensitivity in healthy 
individuals from CL endemic areas [31]. Furthermore, 
we recently showed that previous exposure to Ph. papa-
tasi bites appears to influence the severity of CL [29]. 
As for Ph. sergenti saliva [32], nothing is known about 
its effect in the human immune system or in modulat-
ing CL pathology. The presence of ulcerated nodular 
lesions also showed a strong correlation with L. tropica 
infection in patients from all the CL endemic regions 
where this species was found. Therefore, the infection 
with each of the parasite species appears to favour the 
development of specific clinical feature(s), which vary 
depending on geography and may also impact treatment 
response. More research is needed to establish a correla-
tion between treatment efficacy and the different clinical 
presentations of Old World CL patients.
Approximately 50% of the L. major patients (mainly 
from the Central or Eastern regions) who presented with 
ulcerated nodular lesions had detectable SI. Interestingly, 
there was a statistically significant (Fisher’s exact test, 
P = 0.0001) correlation with the response to re-epithelisa-
tion after treatment with azole/fusidic acid (without fur-
ther administration of SSG) in patients from the Central 
region compared to patients from other endemic areas 
(Fig. 2). This suggests that elimination of the SI appears 
Fig. 3 Percentage of resistant Staphylococcus species isolated from 6 volunteers with L. major lesion in Al Ahsa region of KSA. Only the antibiotics 
with at least one resistant isolate are shown. Fusidic acid is highlighted with a red line underneath the name
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to favour healing of L. major patients from Riyadh and 
Al Ahsa, but has little effect in those from Al Madinah, 
although the lack of response of the latter may be also 
correlate with the time of residency in this region [27, 28]. 
In addition, we cannot rule out that first line of treatment 
could accelerate re-epithelization in patients who may 
have self-healed over time. However, this seems unlikely 
because most of the patients seek medical assistance after 
the lesion has worsened. Moreover, like pathogenic fungi, 
Leishmania parasites make ergosterol, an essential mem-
brane lipid, the synthesis of which is inhibited by azoles 
[33]. Thus, treatment with topical azoles alone may pos-
sibly impact directly on L. major susceptible strains. 
Also, elimination of the fungal or bacterial infection may 
boost the immune system to fight the L. major infection 
in many cases, with the exception being those present-
ing papular lesions from the Al Madinah region. Alter-
natively, the indirect effect that the development of SIs 
may have in the treatment of L. major-infected patients 
could also be a result of the release of bacterial or fun-
gal molecules after application of the first line of treat-
ment. This could activate host immunity and contribute 
to the elimination of L. major infection and subsequent 
activation of wound healing mechanisms [34]. Currently, 
we are performing an extensive metagenomic analysis to 
characterise the microbiota present in lesions from both 
L. major and L. tropica patients. These results will be key 
to associate specific microbial groups with differences in 
treatment response.
It is worth mentioning that in some cases the first 
line of treatment is applied to increase efficacy of SSG 
regime. Regarding L. tropica-infected patients, most 
were unresponsive (60%) to the first course of anti-leish-
manial treatment and healing only occurred in patients 
receiving a second (and sometimes a third) course of 
SSG. Unresponsive cases to SSG have been reported 
among L. tropica patients in neighbour countries 
like Iran [35]. Moreover, it remains to be determined 
whether L. tropica strains from KSA are less sensitive to 
azoles or alternatively, the drug may be more accessible 
to the parasite in L. major lesions than in L. tropica ones.
Novel therapies against CL need to be evaluated in clin-
ical trials in KSA. For example, the oral administration of 
miltefosine, an alkylphosphocholine analogue that inhib-
its phospholipid and sterol biosynthesis, proved to be 
safer and more effective than SSG for the treatment of CL 
caused by L. braziliensis in Brazil [36]. Likewise, it would 
be interesting to test the efficacy of topical paromomycin 
for the treatment of L. tropica infections [25]. None of 
these drugs is used in the current CL treatment regime in 
KSA but could represent alternative approaches in unre-
sponsive cases.
Taken together, differences in the susceptibility to 
either azoles or SSG among parasite strains and resist-
ance against fusidic acid observed for the Staphylococcus 
species isolated from L. major CL lesions suggest that the 
current protocols for CL treatment need to consider not 
only the parasite species, but also the geographical ende-
micity of CL infections. Further research is required to 
understand whether treatment unresponsiveness in KSA 
is also due to the development of drug-resistant para-
sites. Knowing this will help determine if different anti-
leishmanial treatment protocols need to be considered.
Conclusions
The findings of this study demonstrate that patient 
responses to current anti-leishmanial treatment vary 
between the different CL endemic areas and are also par-
tially dependent on the development of SIs. These results 
have implications for the implementation of differential 
treatment regimens according to the CL-endemic area, 
which in turn will save financial resources and ensure 
patients are treated with the most efficacious anti-
leishmanial therapies. It remains to be determined in 
CL-endemic areas from other EMR countries whether 
such profound differences in anti-Leishmania treatment 
responses are also observed among CL patients from dif-
ferent geographical locations.
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Additional file 1: Table S1. Cohort characteristics and relevant clinical 
features.
Additional file 2: Figure S1. Scheme representing the current leishma‑
niasis treatment policy in KSA. Figure S2. Leishmania spp. identification 
in Central Region by PCR‑RFLP analysis of parasite ITS1 region. Lane Lt: L. 
tropica positive control; Lane Lm: L. major positive control; Lanes 1–10: 
different examples of Leishmania isolates from Rass, Dwadmi and Muzah‑
myyah. Figure S3. Leishmania spp identification in Al Madinah Province 
by PCR‑RFLP analysis of parasite ITS1 region. Lanes 1–4: different examples 
of Leishmania isolates from Aljadaida and Sulailah, Al Madinah Province; 
Lanes 1 and 2: L. tropica samples; Lanes 3 and 4: L. major samples; Lane 
Lm: L. major positive control; Lane Lt: L. tropica positive control. Figure 
S4. Leishmania spp. identification in Al Ahsa Region by PCR‑RFLP analysis 
of parasite ITS1 region. Lanes 1–13: different examples of Leishmania 
isolates from Al Ahsa Region; Lane Lt: L. tropica positive control; Lane Lm: 
L. major positive control. Figure S5. Leishmania spp identification in Asir 
Region by PCR‑RFLP analysis of parasite ITS1 region. Lanes 1–5: different 
examples of Leishmania isolates from Asir Province. Figure S6. Distribution 
of Leishmania species (a) and patient response to anti‑leishmanial treat‑
ment (b) within the Eastern region of Saudi Arabia. The map was created 
using software ArcGIS 10 (ESRI, Redlands, CA). Figure S7. Distribution of 
Leishmania species (a) and patient response to anti‑leishmanial treatment 
(b) within the Northwest region of Saudi Arabia. The map was created 
using software ArcGIS 10 (ESRI, Redlands, CA). Figure S8. Distribution of 
Leishmania species (a) and patient response to anti‑leishmanial treatment 
(b) within the southwest region of Saudi Arabia. The map was created 
using software ArcGIS 10 (ESRI, Redlands, CA).
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